Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Opthea in a report issued on Monday, ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

The ASX All Ords dividend stock has come under heavy selling pressure in 2025. It’s now trading on a fully franked 8% ...

The firm’s unlisted high-conviction equities strategy is more than 44 per cent invested in healthcare stocks. The biotech has warned it could be insolvent.

Opthea (NASDAQ:OPT – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to ...

Australian money managers Regal Partners Ltd. and Pengana Capital Group Ltd. are facing increased scrutiny from investors ...

Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.

Fintel reports that on March 25, 2025, Jefferies downgraded their outlook for Opthea Limited - Depositary Receipt () ...

Trading in shares of Opthea remains halted in the U.S. and Australia after the clinical-stage biopharmaceutical company said its lead product candidate, sozinibercept, failed in a late-stage study in ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...